1998
DOI: 10.1016/s0149-2918(98)80060-x
|View full text |Cite
|
Sign up to set email alerts
|

A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
28
0

Year Published

1999
1999
2021
2021

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 57 publications
(29 citation statements)
references
References 13 publications
1
28
0
Order By: Relevance
“…Reimherr et al studied 241 patients receiving either bupropion SR 150 mg/day or bupropion SR 300mg/day and found no effect on QRS duration (12). Wenger and colleagues reported no effect on QRS duration among 23 patients taking therapeutic doses of bupropion (13).…”
Section: Discussionmentioning
confidence: 99%
“…Reimherr et al studied 241 patients receiving either bupropion SR 150 mg/day or bupropion SR 300mg/day and found no effect on QRS duration (12). Wenger and colleagues reported no effect on QRS duration among 23 patients taking therapeutic doses of bupropion (13).…”
Section: Discussionmentioning
confidence: 99%
“…Bupropion hydrochloride sustained release (SR) and sertraline have demonstrated antidepressant efficacy in randomized, double-blind, placebo-controlled studies in outpatients with major depressive disorder (Reimherr et al 1990(Reimherr et al , 1998Fabre et al 1995;Croft et al 1999;Coleman et al 1999). Bupropion has demonstrated comparable antidepressant efficacy to sertraline (Kavoussi et al 1997;Croft et al 1999;Coleman et al 1999), fluoxetine (Feighner et al 1991), and paroxetine (Weihs et al 2000) in outpatients with major depressive disorder.…”
mentioning
confidence: 99%
“…in younger subjects. 13 As always, in the elderly and medically ill, the use of a lower initial dose (e.g., 100 mg or 150 mg daily) and slower titration may be prudent, given the frequency of polypharmacy in the elderly and the effects of aging on pharmacokinetics. 14 A controlled trial of a relatively low dose of bupropion SR, 150 mg/day, thus may be worthwhile in geriatric depression.…”
Section: Discussionmentioning
confidence: 99%